

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**November 17, 2022**

---

**I New Study - Initial Review**

**A082101**, Neoadjuvant Immunotherapy in Sarcomatoid Mesothelioma (Version Date 10/19/22)

---

**II New Study - Initial Review**

**NRG-LU008**, Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (Version Date 09/15/22)

---

**III New Study - Initial Review**

**S2302**, Project Pragmatica: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Version Date 10/18/22)

---

**IV New Study ReReview**

**MM1YA-CTG01**, A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MyeloMATCH Clinical Trial (Version Date 10/18/22)

---

**V Continuing Review**

**A091903**, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma (Version Date 03/09/22)

---

## **VI Continuing Review**

**EA6183**, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D) (Version Date 08/02/21)

---

## **VII Continuing Review**

**EA8134**, InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) (Version Date 05/24/21)

---

## **VIII Continuing Review**

**NRG-HN001**, Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (Version Date 10/03/22)

---

## **IX Continuing Review**

**S1608**, Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (Version Date 05/09/22)

---

## **X Continuing Review**

**S1933**, A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status (Version Date 06/01/21)

---

## **XI Continuing Review**

**S2011**, Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP Trial (Version Date 07/08/21)

---

## **XII Continuing Review**

**S1925**, Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (Version Date 06/10/22)

---

## **XIII Continuing Review**

**NRG-GY025**, A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (Version Date 11/30/21)

---